SCILEX Pharmaceuticals
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
960 San Antonio Rd, Palo Alto, Californi...Phone Number
(650) 516-4310Website
www.scilexpharma.comRevenue
$9.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About SCILEX Pharmaceuticals
Scilex Pharmaceuticals is a company that develops and markets pain management pharmaceuticals. The company was founded in 2011 and is headquartered in San Diego, California.Explore more
SCILEX Pharmaceuticals Org Chart
RP
Manager, Territory Business
JW
Manager, Territory Business
MF
Manager, Territory Business
BP
Manager, Territory Business
RB
Manager, Territory Business
HJ
Manager, Territory Business
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SCILEX Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on SCILEX Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at SCILEX Pharmaceuticals
Check if SCILEX Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
SCILEX Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if SCILEX Pharmaceuticals is spiking on competitors!
Click to see if SCILEX Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once SCILEX Pharmaceuticals has new funding data
Product Launch: Get notified when SCILEX Pharmaceuticals launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to SCILEX Pharmaceuticals
Compare insights from companies similar to SCILEX Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$15.5M
51-200
Private
$31M
2003
JH
James HavilandVice President, Quality Assurance, Regulatory Compliance & Regulatory Affairs
Company Profile Activity
Activity Insights
SCILEX Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SCILEX Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SCILEX Pharmaceuticals.
SCILEX Pharmaceuticals financials insights
Gather financial insights about SCILEX Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$5M
2015
Private Equity
$2M
2020
Debt
$1M
SCILEX Pharmaceuticals Tech Stack
A closer look at the technologies used by SCILEX Pharmaceuticals
Most Recent Scoops
Left Company
Executive Move
Suresh Khemani, Chief Commercial Officer & Senior VP, has left the organization and now serves as Chief Commercial Officer & Senior Vice President at Scilex Holding Co.
Executive Moves, Left Company
Left Company
Executive Move
Jaisim S., Chief Executive Officer & President, has left the organization and now serves as Chief Executive Officer & President at Scilex Holding Co.
Executive Moves, Left Company
Event
Events
Open Position
Open Position
SCILEX Pharmaceuticals News & Media
Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plans
PALO ALTO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced ZTlido is now covered by managed health care plans representing approximately 190 million of the over 300 million covered lives across the UnitScilex, a Sorrento Company, Highlights Safety Data From Phase 1 Trial of SP-104, a Proprietary Low Dose Naltrexone for Fibromyalgia
PALO ALTO, Calif. and SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”) and a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today that safety data from Scilex’s Phase 1 clinical trial demonstrated that SP-104 was better tolerated thanScilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA™) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting
SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain, and it contains no preservatives, surfactants, solvents, or particulates.The study met its primary endpoint with a highly statistically significant reduction in average daily leg pain in patients receiving SEMDEXATM compared to placebo (p<0.001).Data demonstrated the utility of SEMDEXA™ in rapidly reducing sciatica pain with an extended effScilex Holding Company a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., Appoints Highly Accomplished Life Science Executive, Elizabeth Czerepak, as Executive Vice President, Chief Financial Officer (CFO) and Chief Business Officer (CBO)
SAN DIEGO and PALO ALTO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), who is a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that Elizabeth Czerepak will join the company as Executive Vice President, Chief Financial Officer and Chief Business Off
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SCILEX Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Scilex Pharmaceuticals is a company that develops and markets pain management pharmaceuticals. The company was founded in 2011 and is headquartered in San Diego, California.... Read More
